MedTrace Logo

Comparison of Whole Body DWI to FDG PET

NCT06630845 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-03

No results posted yet for this study

Summary

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Conditions

Interventions

DRUG

Fluorodeoxyglucose F18

Given IV as part of routine imaging

PROCEDURE

Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)

Imaging procedure

PROCEDURE

Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)

Imaging procedure done concurrently with PET/MRI

DEVICE

General Electric (GE) SIGNA PET/MR

Imaging device

Sponsors & Collaborators

Principal Investigators

  • Thomas A Hope, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2027-10-31
Completion
2029-10-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06630845 on ClinicalTrials.gov